Scarica l'app Stockscreener
248.91
1.03%
2.54
Dopo l'orario di chiusura:
255.00
6.09
+2.45%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché KRYS Giù?
Forum
Previsione
Precedente Chiudi:
$246.37
Aprire:
$249.51
Volume 24 ore:
424.90K
Relative Volume:
1.48
Capitalizzazione di mercato:
$7.22B
Reddito:
$290.51M
Utile/perdita netta:
$89.16M
Rapporto P/E:
83.25
EPS:
2.99
Flusso di cassa netto:
$119.18M
1 W Prestazione:
+0.96%
1M Prestazione:
+6.35%
6M Prestazione:
+73.66%
1 anno Prestazione:
+58.88%
Intervallo 1D:
$245.99
$255.07
Intervallo di 1 settimana:
$235.60
$257.95
Portata 52W:
$122.80
$265.92
Krystal Biotech Inc Stock (KRYS) Company Profile
Nome
Krystal Biotech Inc
Settore
Industria
Telefono
(412) 586-5830
Indirizzo
2100 WHARTON STREET, PITTSBURGH, PA
Confronta KRYS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
248.91 | 7.14B | 290.51M | 89.16M | 119.18M | 2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-03-05 | Iniziato | Jefferies | Buy |
| 2024-08-06 | Downgrade | Citigroup | Buy → Neutral |
| 2023-11-20 | Iniziato | Goldman | Buy |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-12 | Iniziato | Citigroup | Buy |
| 2023-09-07 | Iniziato | Berenberg | Buy |
| 2023-04-18 | Iniziato | Stifel | Buy |
| 2023-02-28 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-08-25 | Downgrade | Goldman | Buy → Neutral |
| 2022-01-18 | Iniziato | BofA Securities | Buy |
| 2021-07-20 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-09-18 | Iniziato | B. Riley FBR | Buy |
| 2020-06-04 | Iniziato | Evercore ISI | Outperform |
| 2019-09-24 | Iniziato | Goldman | Neutral |
| 2019-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-24 | Reiterato | Chardan Capital Markets | Buy |
| 2019-06-24 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-30 | Iniziato | Guggenheim | Buy |
| 2018-09-11 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Krystal Biotech Inc Borsa (KRYS) Ultime notizie
Krystal Biotech Touts Positive KB407 CF Gene Therapy Data, Eyes Repeat Dosing and Registrational Path - Yahoo Finance
Can Krystal Biotech Inc. stock continue upward trend2025 Support & Resistance & Risk Managed Investment Signals - ulpravda.ru
Will Krystal Biotech Inc. stock benefit from upcoming earnings reportsJuly 2025 Drop Watch & Low Risk Growth Stock Ideas - ulpravda.ru
Will Krystal Biotech Inc. stock benefit from AI adoptionLong Setup & High Accuracy Investment Signals - ulpravda.ru
Krystal Biotech advances KB407 with positive CF trial data - TipRanks
What Wall Street predicts for Krystal Biotech Inc. stock priceJuly 2025 Opening Moves & Free Technical Confirmation Trade Alerts - ulpravda.ru
Krystal Biotech (KRYS) Reports Promising Interim Results from CORAL-1 Study - GuruFocus
Krystal Biotech, Inc. Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study - TradingView — Track All Markets
Will Krystal Biotech Inc. stock reach all time highs in 2025Portfolio Value Summary & Real-Time Market Trend Scan - ulpravda.ru
Krystal Biotech confirms CFTR delivery in CF patients with KB407 By Investing.com - Investing.com India
Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis - Stock Titan
Trend Recap: Will Krystal Biotech Inc. stock reach all time highs in 2025 - ulpravda.ru
How Krystal Biotech Inc. (4KB) stock responds to bond marketWeekly Gains Summary & Fast Moving Market Watchlists - ulpravda.ru
KRYS Stock Surges 57% in a Year: More Upside Potential in 2026? - Finviz
Krystal Biotech to share interim results from cystic fibrosis trial By Investing.com - Investing.com Nigeria
Krystal Biotech Announces Investor Conference Call for Interim Clinical Update on KB407 in Cystic Fibrosis Study - Quiver Quantitative
Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis - The Manila Times
Citigroup Upgrades Krystal Biotech (KRYS) - Nasdaq
Krystal Biotech (KRYS) Receives Upgraded Rating and Price Target Boost from Citigroup | KRYS Stock News - GuruFocus
Krystal Biotech Shares Rise After Citigroup Upgrade - MarketScreener
Citigroup Upgrades Krystal Biotech to Buy From Neutral, Adjusts Price Target to $309 From $198 - marketscreener.com
VIRGINIA RETIREMENT SYSTEMS ET Al Sells 5,800 Shares of Krystal Biotech, Inc. $KRYS - MarketBeat
Krystal Biotech (NASDAQ:KRYS) Shareholders Have Earned a 30% CAGR Over the Last Five Years - 富途牛牛
Krystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Conference - The Globe and Mail
Krystal Biotech, Inc. to Present at 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 - Quiver Quantitative
Will Krystal Biotech Inc 4KB stock outperform global peersPortfolio Update Report & Daily Entry Point Alerts - moha.gov.vn
Krystal Biotech Inc Stock Analysis and ForecastVolume Analysis Techniques & Hedge Fund-Style Analysis Now Free - earlytimes.in
Growth Value: Can Krystal Biotech Inc stock deliver surprise earnings beatM&A Rumor & Fast Gaining Stock Reports - moha.gov.vn
Discipline and Rules-Based Execution in KRYS Response - Stock Traders Daily
Rally Mode: Can Krystal Biotech Inc stock continue upward trendJuly 2025 Fed Impact & AI Powered Buy/Sell Recommendations - moha.gov.vn
Exploring High Growth Tech Stocks In The US For December 2025 - simplywall.st
Krystal Biotech (NASDAQ:KRYS) Sets New 52-Week HighWhat's Next? - MarketBeat
Bearish Setup: Can Krystal Biotech Inc stock continue upward trend2025 Historical Comparison & Safe Entry Momentum Tips - moha.gov.vn
Krystal Biotech, Inc. (KRYS) Stock Analysis: Navigating a $7.31 Billion Market Cap with Promising Genetic Medicines - DirectorsTalk Interviews
Krystal Biotech Earnings Notes - Trefis
Krystal Biotech announces resignation of longtime board member - TipRanks
Krystal Biotech Announces Board Resignation - TradingView — Track All Markets
Krystal Biotech, Inc. Announces Resignation of Kirti Ganorkar as Director, Effective December 31, 2025 - marketscreener.com
Krystal Biotech, Inc. $KRYS Shares Purchased by Voya Investment Management LLC - MarketBeat
Krystal Biotech stock hits all-time high at 248.82 USD By Investing.com - Investing.com Nigeria
Krystal Biotech (NASDAQ:KRYS) Hits New 52-Week HighShould You Buy? - MarketBeat
Krystal Biotech stock hits all-time high at 248.82 USD - Investing.com
Trading the Move, Not the Narrative: (KRYS) Edition - Stock Traders Daily
Why Krystal Biotech Inc. stock remains on buy listsWeekly Risk Report & Real-Time Market Sentiment Reports - Улправда
AI Stocks: Will Krystal Biotech Inc. (4KB) stock profit from AI boomPortfolio Performance Summary & Daily Chart Pattern Signal Reports - Улправда
Why a Fund Placed a $13 Million Bet on Ambarella Stock Before a 20% Post-Earnings Drop - The Motley Fool
Can Krystal Biotech Inc. stock deliver surprise earnings beatLayoff News & Weekly Market Pulse Alerts - DonanımHaber
Is Krystal Biotech Inc. stock attractive for ETFs2025 Investor Takeaways & Precise Trade Entry Recommendations - Улправда
Will Krystal Biotech Inc. (4KB) stock profit from AI boomJuly 2025 News Drivers & Weekly High Conviction Ideas - Улправда
Three Stocks That May Be Priced Below Their Estimated Worth In December 2025 - Sahm
Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years - Sahm
Krystal Biotech Inc Azioni (KRYS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):